 Pyrazoles
"Pyrazoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with IMIDAZOLES in which they are at the 1,3 positions.
| Descriptor ID |
D011720
|
| MeSH Number(s) |
D03.383.129.539
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyrazoles".
Below are MeSH descriptors whose meaning is more specific than "Pyrazoles".
This graph shows the total number of publications written about "Pyrazoles" by people in this website by year, and whether "Pyrazoles" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 | | 1997 | 0 | 1 | 1 | | 1999 | 0 | 1 | 1 | | 2001 | 1 | 0 | 1 | | 2002 | 0 | 1 | 1 | | 2003 | 0 | 2 | 2 | | 2004 | 4 | 0 | 4 | | 2005 | 1 | 1 | 2 | | 2006 | 4 | 2 | 6 | | 2007 | 1 | 0 | 1 | | 2008 | 5 | 3 | 8 | | 2009 | 2 | 1 | 3 | | 2010 | 9 | 2 | 11 | | 2011 | 5 | 5 | 10 | | 2012 | 14 | 9 | 23 | | 2013 | 14 | 9 | 23 | | 2014 | 5 | 3 | 8 | | 2015 | 12 | 4 | 16 | | 2016 | 5 | 12 | 17 | | 2017 | 7 | 6 | 13 | | 2018 | 8 | 4 | 12 | | 2019 | 8 | 5 | 13 | | 2020 | 5 | 6 | 11 | | 2021 | 13 | 10 | 23 | | 2022 | 1 | 11 | 12 | | 2023 | 0 | 6 | 6 | | 2024 | 12 | 7 | 19 | | 2025 | 9 | 7 | 16 |
To return to the timeline, click here.
Below are the most recent publications written about "Pyrazoles" by people in Profiles.
-
Pittman JE, Morgan S, McCreary M, Vu PT, Jorth P, Heltshe S, Hoffman LR, Kelly A, Sagel SD, Singh PK, Solomon GM, Rosenfeld M, Ratjen F. Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in 6- to 11-Year-Olds with Cystic Fibrosis: An Observational Study. Ann Am Thorac Soc. 2025 Nov; 22(11):1696-1708.
-
Durieu I, Clements B, Fabrizzi B, Mall MA, McKone E, Ramsey B, Tullis E, Taylor-Cousar JL, van der Meer R, Bachman E, Chin A, Conner S, Jennings M, Weinstock T, Colombo C, Robinson P. Impact of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance and Abnormal Glucose Metabolism: A Phase 3b, Open-Label Clinical Trial. Am J Respir Crit Care Med. 2025 Oct; 211(10):1926-1934.
-
Daines CL, Polineni D, Tullis E, Costa S, Linnemann RW, Mall MA, McKone EF, Quon BS, Ringshausen FC, Selvadurai H, Taylor-Cousar JL, Withers NJ, Sawicki GS, Lee T, Ahluwalia N, Morlando Geiger J, Jennings M, Tan YV, Waltz D, Ramsey B, Griese M. Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Adults and Adolescents with Cystic Fibrosis and at Least One F508del Allele: A Phase 3 Open-Label Extension Study. Am J Respir Crit Care Med. 2025 10; 211(10):1901-1914.
-
Wainwright C, McColley SA, McNally P, Powers M, Ratjen F, Rayment JH, Retsch-Bogart G, Roesch E, Ramsey B, McKone EF, Tullis E, Mall MA, Taylor-Cousar JL, Waltz D, Ahluwalia N, Chu C, Scirica CV, Davies JC. Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children =6 Years with Cystic Fibrosis and at Least One F508del Allele: A 192-Week, Phase 3, Open-Label Extension Study. Am J Respir Crit Care Med. 2025 Oct; 211(10):1915-1925.
-
Shimamura A, Maschan A, Bennett C, Samarasinghe S, Farrar JE, Li CK, Sirachainan N, Pongtanakul B, Komvilaisak P, Zubarovskaya L, Rothman JA, Walkovich K, Nakano TA, Bertuch AA, Ferrao A, Bhat R, Hanna R, Overholt K, Boklan J, Wong TF, Wang Q, Urban P, Strahm B, Wang W, Vlachos A, Williams DA. Eltrombopag in combination with immunosuppressive therapy in pediatric severe aplastic anemia: phase 2 ESCALATE trial. Blood Adv. 2025 Aug 12; 9(15):3728-3738.
-
Chan CL, Shirley Bezerra M, Stefanovski D, Gallop RJ, Walega R, Donaldson SH, Frederick CA, Freedman SD, Gelfond D, Hoffman LR, Narkewicz MR, Rowe SM, Sagel SD, Schwarzenberg SJ, Solomon GM, Stalvey MS, Kelly A. Glycemia and Insulin Secretion in Cystic Fibrosis 2 Years After Elexacaftor/Tezacaftor/Ivacaftor: PROMISE-ENDO. J Clin Endocrinol Metab. 2025 Aug 07; 110(9):2674-2684.
-
Abi-Aad SJ, Trocchia C, Mosha M, Mark JA, Leung DH, Khalaf R. Gastrointestinal Burden in Patients With Pancreatic Insufficient Cystic Fibrosis Before and After Elexacaftor/Tezacaftor/Ivacaftor Use. Pancreas. 2025 Nov-Dec 01; 54(10):e858-e862.
-
Talpaz M, Gerds AT, Lyons R, Langmuir P, Hunter D, Lamothe B, Hou K, McMahon B. A phase 2 study of itacitinib alone or in combination with low-dose ruxolitinib in patients with myelofibrosis. Leuk Res. 2025 Aug; 155:107732.
-
Liu JF, Colombo N, Oza AM, Frenel JS, Corr BR, Rubinstein MM, Nevadunsky NS, Lheureux S, Gaba L, González Cortijo L, Salutari V, You B, Chiang S, O'Connor MJ, Oplustil O'Connor L, Meulendijks D, Khatun M, Ghiorghiu D, Oaknin A. ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine Serous Carcinoma. J Clin Oncol. 2025 Sep 10; 43(26):2897-2907.
-
Yamazaki S, Kaneko S, Shimbo A, Irabu H, Ogino R, Miyamoto T, Izawa K, Segawa Y, Kakizaki J, Mori M, Shimizu M. Overlapping Aicardi-Goutières and Singleton-Merten syndromes with a heterozygous gain-of-function mutation in IFIH1 mimicking juvenile idiopathic arthritis. Immunol Med. 2025 Sep; 48(3):256-260.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|